Bilaketaren emaitzak - Jacob M. Rowe

Forward into the second century of Haematologica nork Jacob M. Rowe

Testu osoa

The “7+3” regimen in acute myeloid leukemia nork Jacob M. Rowe

Testu osoa

Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS nork Yishai Ofran, Jacob M. Rowe

Testu osoa

Chimeric antigen receptor therapy for T-cell acute lymphoblastic leukemia: finally catching up with B-cell leukemia? nork Ofrat Beyar-Katz, Jacob M. Rowe

Testu osoa

Traumatic vs. atraumatic 22 G needle for therapeutic and diagnostic lumbar puncture in the hematologic patient: a prospective clinical trial nork Ronit Lavi, Jacob M. Rowe, Irit Avivi

Testu osoa

Toward further excellence in <i>Haematologica</i> nork Jacob M. Rowe, Carlo Balduini, Jerry Radich

Testu osoa

Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia nork Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert

Testu osoa

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia nork Chezi Ganzel, Mira Kharit, Chen Duksin, Jacob M. Rowe

Testu osoa

Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission nork Marc Buyse, Stefan Michiels, Pierre Squifflet, Kathryn J. Lucchesi, Kristoffer Hellstrand, Mats L. Brune, Sylvie Castaigne, Jacob M. Rowe

Testu osoa

A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hod... nork Eldad J. Dann, Rachel Bar-Shalom, Ada Tamir, Ron Epelbaum, Irit Avivi, Menachem Ben-Shachar, Diana Gaitini, Jacob M. Rowe

Testu osoa

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction nork Meira Yisraeli Salman, Alexander R. Terry, Andriy Derkach, David Nemirovsky, Kuo-Kai Chin, Yannis K. Valtis, Leora Boussi, Theresa Spivey, Wenbin Xiao, Christopher Famulare, Jenna Ciervo, Jacob M. Rowe, Martin S. Tallman, Eytan M. Stein

Testu osoa

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study nork Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe

Testu osoa

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900 nork Hugo F. Fernandez, Zhuoxin Sun, Mark R. Litzow, Selina M. Luger, Elisabeth Paietta, Janis Racevskis, Ross L. Levine, Jay P. Patel, Omar Abdel-Wahab, Rhett P. Ketterling, Gordon W. Dewald, John M. Bennett, Jacob M. Rowe, Hillard M. Lazarus, Martin S. Tallman

Testu osoa

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia nork Nicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, Adele K. Fielding, Anjali Advani, Renato Bassan, Victoria Chia, Michael Doubek, Sebastian Giebel, Dieter Hoelzer, Norbert Ifrah, Aaron Katz, Michael Kelsh, Giovanni Martinelli, Mireia Morgades, Susan O’Brien, Jacob M. Rowe, Julia Stieglmaier, Martha Wadleigh, Hagop Kantarjian

Testu osoa

The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial nork David I. Marks, Anthony V. Moorman, Lucy Chilton, Elisabeth Paietta, Amir Enshaie, Gordon DeWald, Christine J. Harrison, Adele K. Fielding, Letizia Foroni, Anthony H. Goldstone, Mark R. Litzow, Selina M. Luger, Andrew K. McMillan, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Peter Wiernik, Hillard M. Lazarus

Testu osoa